Drug Trial Radar · NCT05757856
A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis
Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Jan 20, 2023
Primary completion
May 22, 2025
Study completion May 22, 2025
Sponsor
- Lead sponsor
- NexEos Diagnostics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An open-label phase 2 study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 and NDX-3324 in healthy participants and patients with eosinophilic esophagitis (EoE).
Conditions
- Eosinophilic Esophagitis
Interventions
NDX-3315Drug
Oral solution
NDX-3324Drug
Oral solution
SPECT/CT ImagingDiagnostic test
Participants undergo SPECT/CT imaging following administration of NDX-3315 or NDX-3324.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of all participants with AEs following administration of NDX-3315 and NDX-3324Time frame: From start of study drug administration up to End of Study (EOS) ( Up to 3 Weeks)
- Peak eosinophil counts per high-power field (HPF)Time frame: Up to 10 days after last dose
- Absolute quantification of SPECT imagingTime frame: Up to 45 minutes after dose
- Determine Concordance of OutcomesTime frame: Up to 10 Days After Last Dose
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Northwestern Univerisity
Chicago, Illinois
University of Pennsylvania
Philadelphia, Pennsylvania
University of Utah
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.